Maharashtra: Wanbury Limited has announced that it has been awarded a Certificate of Suitability (CEP) by the European Directorate for the Quality of Medicines (EDQM) for its
Dextromethorphan active pharmaceutical ingredient (API), antitussive (cough) medicine.The global formulation market for Dextromethorphan is valued at USD 2,500 million for
FY24, having grown by 7% over the past year. “With the CEP certification, Wanbury is well positioned to initiate the commercial sales of this product in European markets,” the Compamy stated in a BSE filing.Read also: Wanbury ropes in Prakash Venkatraman as President of API businessWanbury Limited has a presence in API global market and domestic branded Formulation. Wanbury strength lies in Active Pharmaceutical Ingredient (API) Sales & Marketing in over 50 countries and Pan-India Formulation presence. The Company has a basket of over 13 API products. It has the larger customer base in Europe & US for Tramadol & Setraline (API).The Company has two US-FDA approved multi-product API facilities and one plant under operation for semi-regulated markets. It has pan-India presence in ethical formulations with a portfolio of close to 70 brands.
Read also: MSD Pharma gets CDSCO Panel nod to update prescribing information of Human Papillomavirus 9-valent Recombinant Vaccine